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ABSTRACT
Canine parvovirus type 2 (CPV-2) is a highly
contagious viral disease with three variants (CPV-2a,
CPV-2b and CPV-2c) currently circulating in dogs
worldwide. The main aim of this study was to
determine the prevalent CPV-2 variant in faecal
samples from 53 dogs presenting with acute
gastroenteritis suspected to be and consistent with
CPV-2 to Nigerian Veterinary Clinics in 2013–2014.
Seventy-five per cent of these dogs tested positive for
CPV-2 in a commercial antigen test and/or by PCR.
Partial sequencing of the VP2 gene of six of these
demonstrated them to be CPV-2a. Most of the dogs
(60 per cent) were vaccinated, with 74 per cent of
them puppies less than six months old.
INTRODUCTION
Canine parvovirus-2 (CPV-2) is a contagious
viral disease of dogs characterised by severe
diarrhoea with a high mortality rate. Three
variants of CPV-2 (CPV-2a, CPV-2b and
CPV-2c) are currently reported to be circulat-
ing worldwide with regional differences in
which variants predominate (Cavalli and
others 2008). There are few reports on the
genetic characterisation of CPV-2 and its var-
iants in Africa. All three variants were
reported to be circulating in Tunisia (Touihri
and others 2009) and Morocco (Amrani and
others 2016), whereas Dogonyaro and others
(2013) reported CPV-2a and CPV-2b in
South Africa and CPV-2a only in Nigeria.
The main aim of the current study was to
determine the variants of CPV-2 currently cir-
culating in Nigeria.
MATERIALS AND METHODS
Samples were collected from 53 dogs pre-
senting with clinical signs of acute gastro-
enteritis at three different veterinary clinics
in Nigeria: Magma and Mokola vet clinics in
Ibadan (n=49), Vetworld Veterinary Clinic in
Abuja (n=3) and the Veterinary Teaching
Hospital in Makurdi (n=1). This research
was approved by the University of
Nottingham School of Veterinary Medicine
and Science Ethical Review Committee. The
consent of dog owners was obtained verbally
and demographic information was also col-
lected. Samples were tested for CPV-2 at
point of care using the SNAP Parvo Antigen
Test (IDEXX). In addition, samples were col-
lected onto Whatman FTA cards, which were
then stored at room temperature before
transport to the University of Nottingham for
molecular analysis.
DNA was isolated from the stored faecal
samples using the QIAamp DNA stool mini
kit (Qiagen, Germany) following the manu-
facturer’s standard protocol for pathogen
detection with the following exceptions. Ten
punches were removed from the Whatman
FTA card into a 2 ml centrifuge tube using a
3-mm punch and matt (Harris Puncher).
Beater beads and buffer ASL (Qiagen) were
added and incubated at 70°C for three hours
in a heating block (Grant Instrument,
England). The incubated samples were vor-
texed ( JenconsS) at 30-minute intervals to
ensure adequate homogenisation, lysis of
CPV-2 virus capsid and recovery of dried
faecal samples from the Whatman FTA cards.
Sample centrifugation was done at
11,000 rpm in a bench-top centrifuge for
10 minutes before and after addition of
inhibitEx tablets (Qiagen). Half of the
recommended volume of elution buffer (AE,
Qiagen) was used, the elution buffer was
heated at 70°C for ﬁve minutes before
elution and sequential elution was done to
ensure maximum DNA yield. Further DNA
concentration was performed via vacuum
centrifugation (Christ, Germany) set at 30°C
for an average of 20 minutes. DNA concen-
trations were measured using Nanodrop
8000 spectrophotometer (Thermo Scientiﬁc)
before PCR was performed. Positive control
DNA for the CPV-2 VP2 was derived from
freeze-dried Novibac parvo vaccine (MSD
Animal Health, UK) using the same protocol
as for the faecal samples.
PCR was performed on all the samples
extracted using two sets of published primers
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and protocols to amplify the CPV-2 VP2 gene (Touihri
and others 2009), and one set for canine GAPDH ampli-
ﬁcation (Tarlinton and others 2013a). Details of the
primers and amplicons are provided in Table 1. The
50-μl PCR master mix reaction prepared consisted of
100-μM dNTP (BioLabs), 20-ρmol forward primer,
20-ρmol reverse primer (Euroﬁns), 10X standard Taq
(magnesium-free) reaction buffer (BioLabs), 3-μM mag-
nesium chloride, ﬁve units of DNA Taq polymerase
(BioLabs), 31 μl of RNase-free water (BioLabs) and 1 μl
of the template. The thermal cycling conditions involved
95°C of initial denaturation for 10 minutes, followed by
30 cycles of denaturation at 95°C for 30 seconds, 55.5°C
annealing temperature for 30 seconds, extension at 72°C
for 3 minutes with a ﬁnal extension at 72°C for
15 minutes using a Techne TC-512 PCR machine.
Following gel electrophoresis to conﬁrm ampliﬁcation,
PCR products were puriﬁed using the Nucleospin
extract II kit (Machery-Nagel). Samples were sequenced
by the Sanger method by Source BioScience.
Statistical analysis (chi-square) was performed using
IBM Statistical Package for the Social Sciences software
V.22, 32 bits edition with a cut-off for statistical signiﬁ-
cance of 0.05.
RESULTS
The demographic summary of the animals tested with
the SNAP Parvo Antigen Test is presented in Table 2. Of
dogs presenting with acute gastroenteritis, 74 per cent
were puppies less than six months of age, with non-
indigenous breeds (Alsatian, Boerboel, bull mastiff,
Caucasian shepherd dog, Neapolitan mastiff, Rottweiler
and terrier) making up 92 per cent of the cases. The
majority (60 per cent) were vaccinated, though in most
cases vaccination history was incomplete, confounding
further analysis. Sixty-four per cent tested positive for
CPV-2 with the SNAP Parvo Antigen Test. No statistically
signiﬁcant associations between CPV-2 test status and
demographic characteristics were seen by chi-square.
Twenty samples were positive by PCR using the short
VP2 gene primers, but PCR product was only obtained
for eight of these with the long VP2 gene primers. This
indicates that recovery of DNA from the Whatman FTA
cards was an issue. Furthermore, only two samples tested
positive for GAPDH, which was included as a quality
control reference gene. Only 15 samples produced
sequence suitable for genetic analysis (six long and nine
short); these have been submitted to GenBank (acces-
sion numbers KX192407–KX192421). The short CPV-2
VP2 gene PCR detected 14 (26.4 per cent) of the
samples that were positive by the SNAP Parvo Antigen
Test and an additional 6 (11.3 per cent) that were not
detected by the antigen test. Full details of all the
animals and their test results are presented in online
supplementary ﬁle 1. Poor recovery of DNA from the
Whatman FTA cards makes interpretation of those
samples that did not amplify in PCR as true negative
rather than assay failure difﬁcult; therefore, negative
results are not recorded. Analysis of the translated
amino acid sequences of the Nigerian samples demon-
strated that all of the isolates fell within the CPV-2/2a
clade with an asparagine residue at position 426 of the
VP2 gene (Table 3). This is the characteristic amino acid
distinguishing CPV-2/2a from CPV-2b (aspartic acid)
and CPV-2c (glutamic acid) (Cavalli and others 2008).
The longer sequences also encompass amino acid 305;
the tyrosine present at this position is characteristic of
CPV-2a as opposed to CPV-2 (Hoelzer and Parrish
2010).
DISCUSSION
The presence of canine parvovirus was conﬁrmed by
SNAP Parvo Antigen Test and/or PCR for most (75 per
cent) of the Nigerian dogs that presented with clinical
signs of CPV-2 in this study, indicating that a presump-
tive clinical diagnosis is reasonably reliable. The
common assumption that native breed dogs are resistant
to CPV-2 infection or disease cannot be determined as
only four native breed dogs were present in this data set.
This bias may simply reﬂect a preference for imported
breeds by clients who can afford veterinary care for com-
panion animals in Nigeria. This is supported by reports
that 66 per cent of the case load of Nigerian clinics are
‘non-indigenous’ dogs (Otolorin and others 2014).
Although PCR is generally more sensitive than the
IDEXX antigen test (Decaro and others 2013), the low
TABLE 1: List of primers used for PCR amplification of canine parvovirus type 2 (CPV-2) VP2 gene and canine GAPDH
gene
Primer name Sequences Size (bp) Reference
CPV-2 VP2 Touihri and others (2009)
VP2-long–forward 5′ GAGCATTGGGCTTACCA 3′ 1195
VP2-long–reverse 5′ TTAATATAATTTTCTAGGTGCTAGTTGAGA 3′
VP2-short–forward 5′ GGTGATCCAAGATATGCATTTGG 3′ 430
VP2-short–reverse 5′ GCAAGATGCATCAGGATC 3′
GAPDH Tarlinton and others (2013a)
GAPDH forward 5′-GAGAAAGCTGCCAAATATG-3′ 193
GAPDH reverse 5′-CCAGGAAATGACCTTGACA-3′
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DNA recovery evident for these samples has likely resulted
in a high degree of PCR failure rather than a true negative
test. Hence, the authors have only presented demographic
summaries for the IDEXX-conﬁrmed cases where the posi-
tive/negative test status is more reliable. Sequence analysis
of 15 of the PCR-positive samples demonstrated CPV-2/2a
sequences only. Six of these samples, where longer PCR
products were obtained, were deﬁnitively CPV-2a, the
remaining nine for which only short sequences were
obtained were CPV-2 or CPV-2a. However, as CPV-2 is not
considered to have circulated since its replacement by
CPV-2a worldwide in the 1980s and detection of vaccine
strains even in dogs recently vaccinated does not com-
monly occur (Miranda and Thompson 2016a, b), it is very
likely that these are CPV-2a. The only other residue that
differed from the reference CPV-2a sequence in the
longer PCR products (Table 3) has been reported in iso-
lates from other countries previously (Yoon and others
2009). This is consistent with the ﬁndings from a previous
South African study, which also reported CPV-2a in the
only two samples sequenced from Nigerian dogs
(Dogonyaro and others 2013). There are reports by
Nigerian veterinarians that canine parvovirus is common
in vaccinated dogs (Shima and others 2015), which is
upheld by these data. The current commercial vaccines
used in Nigeria contain live attenuated strains of CPV-2 or
CPV-2b, which are reported to provide adequate protec-
tion from CPV-2a challenge (Cavalli and others 2008).
However, there are both anecdotal and published reports
of single-dose vaccine regimens being used in dogs in
Nigeria (possibly due to cost concerns for the clients)
(Shima and others 2015, Babalola and others 2016).
These vaccine regimens are unlikely to provide adequate
immunity to CPV-2 in juvenile animals. Interference with
CPV-2 vaccine efﬁcacy by prolonged maternal immunity,
particularly in environments where dogs are exposed to
high levels of viral challenge and bitches are likely to have
a high antiviral titre to pass to puppies, is a well-described
cause of failure of canine parvovirus vaccination (Ling and
others 2012). The young age of most of the animals pre-
sented for gastroenteritis in this study, combined with a
single-dose vaccination regimen, is the most likely reason
for the high number of cases in vaccinated dogs. A further
potential caveat is that without knowledge of the sequence
of all the CPV-2 vaccines in use in Nigeria (some produced
by international ﬁrms, some produced locally), we cannot
exclude detection of vaccine strains as an explanation for
these results. However, recent studies (Miranda and
Thompson 2016a) in European dogs would indicate that
shedding of CPV-2 virus strain after live virus vaccine
administration is rare, with vaccine strains not detected in
clinical samples (even from dogs vaccinated within 10 days
of developing clinical signs of CPV-2).
Further exploration of vaccination practice by
Nigerian veterinarians, sequencing of the vaccine strains
in use in Nigeria for comparison with ﬁeld infections
and more detailed information on vaccine timing and
status with comparison to the onset of clinical are
obvious follow-on studies to explore the underlying
reasons for the high level of CPV-2 disease seen in vacci-
nated dogs.
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TABLE 3: Variations in amino acid residues of the VP2
capsid protein sequence of Nigerian samples compared
with the canine parvovirus type 2 (CPV-2a) reference
strain EU659118
Amino acid 305 324 426 440 564
Reference Y Y N T S
NG32 . I . A .
NG33 . I . A .
NG35 . I . A .
NG36 . I . A I
NG39 . I . A .
NG40 . I . A .
NG21 ND ND . A ND
NG22 ND ND . A ND
NG24 ND ND . A ND
NG25 ND ND . A ND
NG26 ND ND . A ND
NG27 ND ND . A ND
NG29 ND ND . A ND
NG37 ND ND . A ND
NG38 ND ND . A ND
Amino acids identical to the reference strain are indicated by a ‘.’
Residues that allow CPV-2 variants to be distinguished are
highlighted in bold typeface (426 distinguishes CPV-2 and
CPV-2a from CPV-2b and CPV-2c, and 305 further distinguishes
CPV-2 from CPV-2a)
ND, not done (only shorter sequence available); GenBank
accession numbers for these sequences are KX192407–
KX192421
TABLE 2: Demographic data of canine parvovirus type 2
cases based on SNAP Parvo Antigen Test result
Positive Total
Category No. % No. %
Age (months)
≤ 6 26 49 39 74
≥6 8 15 14 26
Vaccination status
Vaccinated 23 43 32 60
Unvaccinated 5 9 11 21
Unknown 6 11 10 19
Breed
Native dogs 1 2 4 8
Non-native dogs 33 62 49 92
Gender
Female 18 34 25 47
Male 16 30 28 53
Total 34 64 53 100
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